Q-omics provides the consensus-scored MAP2K6 profile across patient tissues and cancer cell-line models. MAP2K6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAP2K6 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, MAP2K6 RNA expression shows 18,624 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where MAP2K6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP2K6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP2K6 survival associations across molecular data types. MAP2K6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP2K6 RNA expression–survival associations across cancer types. High MAP2K6 expression shows unfavorable associations in UVM, LUAD and LIHC, but favorable associations in KIRC, BRCA and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAP2K6 RNA expression.
This table summarizes MAP2K6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAP2K6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP2K6 shows lower tumor expression in THCA, KICH, BRCA and COAD and higher tumor expression in UCEC and LUAD. The THCA box plot shows higher MAP2K6 RNA expression in normal versus tumor tissue (log2 FC = −0.633, t-test p < 0.001).
This table shows molecular features associated with MAP2K6 in patient tissues and cancer cell lines. In patient samples, MAP2K6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP2K6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Myeloma.
